Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions, received three drug license suspension orders from state drug control authorities. The affected stores are located in Swarnasandra Mandya (Karnataka, 3-day suspension), Lawyerpet Ongole (Andhra Pradesh, 7-day suspension), and Agaram Road Selaiyur (Tamil Nadu, 3-day suspension). The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The total potential revenue loss from these suspensions is approximately Rs 2.74 lakhs. The company has disclosed the details as required under SEBI Listing Regulations.
The financial impact is negligible at around Rs 2.74 lakhs in potential revenue loss, so this is not material to the company's overall operations or financials. However, multiple license suspensions across different states may raise minor concerns about regulatory compliance and operational consistency at store level.